20 results about "Mesalazine" patented technology

A use of oleanolic acid-28-O-β-D-glucopyranoside in the preparation of an anti-colitis drug is provided. The oleanolic acid-28-O-β-D-glucopyranoside has significant anti-ulcerative-colitis activity compared with parent nucleus oleanolic acid and other analogues, and has equivalent efficacy compared with Mesalazine, a first-line drug for the clinical treatment of inflammatory bowel disease, and can also avoid salicylic acid anaphylaxis possibly caused by Mesalazine western medicine treatment, thereby achieving a good application prospect.

The invention discloses preparation and application of a liquid metal micro-nano robot for treating colitis, and belongs to the technical field of biomedical materials and micro-nano robots. The liquid metal micro-nano robot is prepared by taking liquid metal micro-droplets as a core, coating the surface of the liquid metal micro-droplets with a polyelectrolyte multilayer film through a layer-by-layer self-assembly technology, and loading a medicine (such as mesalazine) for treating colitis in the polyelectrolyte multilayer film. The liquid metal micro-nano robot realizes colon targeted aggregation after oral administration, and can generate autonomous movement and photothermal effect under the irradiation of near-infrared light, thereby realizing phototropic targeted aggregation, photothermal triggering of drug release, and drug delivery and drug delivery. The problems that an existing mesalazine preparation is low in targeted delivery efficiency and a chemically-driven micro-nano robot is low in targeted delivery efficiency in a colon area are solved.

The invention discloses a method for synthesizing mesalazine and application of mesalazine. The method comprises the following steps: introducing p-nitrophenol, formic acid and a Cu-Co-coated MFI-NS molecular sieve catalyst into a continuous flow reaction zone, and sequentially carrying out electrophilic substitution and nitro hydrogenation cascade reaction at normal pressure and 50-70 DEG C; the catalyst has a micropore-mesopore stepped pore channel, and contains a Cu0 metal cluster and a framework Co < 2 + > acid site. And separating, acidifying and crystallizing the reaction liquid to obtain a finished product. According to the invention, the shape-selective selectivity and difunctional synergistic effect of the molecular sieve are utilized, high conversion rate (gt, 98%) and high selectivity (gt, 94%) under mild conditions are realized, the product purity is greater than or equal to 99.5%, and the Cu / Co residue meets the ICHQ3D standard. The catalyst can be recycled for 10 times or more, the yield is reduced by 5% or less, iron mud pollution of a traditional iron powder method and the metal leaching risk of a noble metal catalyst are thoroughly eliminated, and the method has the remarkable advantages of being environmentally friendly, efficient, low in cost, easy to industrially amplify and the like and is suitable for preparing the medicine for treating the inflammatory bowel disease.

The present application relates to a new use of halogenophenol compound 4,5,2'-trihydroxy-2,5'-dibromobenzophenone, in particular in the preparation of a drug for treating inflammatory bowel disease. The halogenophenol compound of the present application can significantly alleviate the weight loss and colon shortening of the colonitis model, reduce the disease activity index of the colonitis model, reduce the inflammatory cell infiltration of the colonitis model, reduce the expression of inflammatory factors, has an immune regulation function on the intestinal tract, and is superior to the clinical first-line drug mesalazine in most indicators, and has application prospects in the treatment of inflammatory bowel disease.

The invention discloses a preparation method and application of stable slow-release hydrogel, and belongs to the technical field of medical biological materials. An ammoniated polycaprolactone-polyethylene glycol carboxyl block copolymer (PCL-PEG-COOH) is self-assembled in a water-absolute ethyl alcohol system to form micelles, uniform catalytic sites are provided for tetraethyl orthosilicate, slow hydrolytic polycondensation of the tetraethyl orthosilicate is regulated and controlled, oriented deposition of silicon dioxide on the surface and cavities of the hydrogel is achieved, and the hydrogel is prepared. And constructing the composite hydrogel with a rigid structure and controllable pores. The hydrogel can efficiently load mesalazine and is stable and slow-released. The technical problems that traditional hydrogel is poor in mechanical stability and burst in drug release are solved, the accuracy and safety of ulcerative colitis treatment are improved, and the hydrogel has good clinical transformation potential.

This invention discloses a traditional Chinese medicine composition for treating ulcerative colitis, its preparation method, combined drugs, and applications. The traditional Chinese medicine composition for treating ulcerative colitis of this invention is made from the following raw materials in parts by weight: Astragalus membranaceus 13-26 parts, Lonicera japonica 10-20 parts, Sargentodoxa cuneata 10-20 parts, Prunus mume 8-16 parts, Agrimonia pilosa 8-16 parts, Allium macrostemon 6-12 parts, Platycodon grandiflorus 6-12 parts, Coptis chinensis 3-6 parts, and Panax notoginseng powder 1-3 parts. An animal model of ulcerative colitis was constructed using DSS induction, and the results showed that the traditional Chinese medicine composition of this invention has a certain therapeutic effect on ulcerative colitis. Clinical studies showed that the traditional Chinese medicine composition of this invention, used in combination with mesalazine enteric-coated tablets, can reduce the modified Mayo score and serum inflammatory markers in patients with active ulcerative colitis, improve colonic mucosal inflammation and gastrointestinal symptoms, and effectively treat active ulcerative colitis of the damp-heat type.

The invention belongs to the technical field of biological medicines, and particularly relates to application of mesenchymal stem cells combined with mesalazine in preparation of an anti-IBD (infectious bursal disease) medicine. The mesenchymal stem cells are mesenchymal stem cells from human umbilical cord; the human umbilical cord mesenchymal stem cells highly express CD73, CD90 and CD65, and low express CD34, CD45 and HLA-DR (Human Leukocyte Antigen-DR). The research finds that the hUC-MSCs has a remarkable treatment effect on a chronic IBD mouse model when being singly used or combined with 5-ASA for treatment, the hUC-MSCs and drug combination can restore the intestinal microecological balance by adjusting the composition of intestinal flora so as to improve the symptoms of IBD, and the hUC-MSCs and the drug combination have a synergistic effect when being combined with 5-ASA for treatment. The invention provides a new thought and experimental basis for clinical treatment of IBD.

The invention discloses a traditional Chinese medicine composition for treating ulcerative colitis, the traditional Chinese medicine composition for treating ulcerative colitis comprises an oral traditional Chinese medicine composition and an enema traditional Chinese medicine composition, and by optimizing the components and the content proportioning relationship among the components and simultaneously matching the components for use, ulcerative colitis ineffective in mesalazine can be improved, and the ulcerative colitis can be effectively treated. The traditional Chinese medicine composition especially improves clinical symptoms and enteroscopy performance of refractory ulcerative colitis, and is remarkable in curative effect, few in side effect and low in recurrence rate.

The application belongs to the technical field of medicine synthesis and specifically relates to a preparation method of mesalamine. In the application, ethylene glycol is used to replace water as a reaction solvent in a substitution reaction, the reaction temperature can be increased to 130-140 DEG C, the reaction time is shortened to 3-4 hours, after the substitution reaction is completed, direct cooling and crystallization are carried out, 5-nitrosalicylate is separated, and the mother liquor can be directly used for the next batch of substitution reaction after adding alkali, so that the ethylene glycol and excess alkali can be reused, no waste water and waste liquid are generated, the production cycle is short, the process is simple, the operation is simple, the "three wastes" are less, and the application is green and environmentally friendly.

The present application relates to a kind of pump control administration system and its execution method for mesalamine enema preparation, belong to the technical field of drug delivery and intelligent administration control. Among them, system includes holding / adapting component, drive assembly, controller, user interaction unit;Holding / adapting component is used to position commercial packaging container, so that commercial packaging container is in sealing communication with output passage, and commercial packaging container is in the driving range of drive assembly, drive assembly is used to apply action to commercial packaging container to output liquid medicine;At least one set of candidate delivery parameter set associated with mesalamine enema preparation is stored or called in controller, and a set of target delivery parameters in candidate delivery parameter set is determined, and local safety check is carried out on target delivery parameter;After local safety check passes and user actively confirms, control drive assembly executes output operation according to target delivery parameter. Pumping execution control to mesalamine enema preparation existing commercial package is realized.

The invention discloses a mesalazine colon-targeted drug delivery transfer system as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The transfer system comprises a mesalazine drug carrier skeleton, an enzyme sensitive component and a pH sensitive coating, the enzyme-sensitive component wraps the outer layer of the mesalazine drug carrier skeleton or is mixed with the mesalazine drug carrier skeleton; the pH-sensitive coating wraps the outer layer of the enzyme-sensitive component or the outer layer of the mixture of the enzyme-sensitive component and the mesalazine drug carrier skeleton. A unique enzyme-sensitive and pH-sensitive double-layer coating technology is adopted, so that enzymatic degradation of mesalazine in a gastric acid environment and the upper section of a small intestine is effectively protected, and early release and whole-body absorption of drugs are remarkably reduced; it is ensured that mesalazine is efficiently and intensively released in the colon environment; the bioavailability of mesalazine in a colon focus is improved, and the local treatment effect is enhanced; the systemic exposure of mesalazine is reduced, and potential systemic adverse reactions are reduced.

The invention relates to carbon monoxide releasing molecules, and methods, compositions and uses relating thereto. Provided is a compound representing a carbon monoxide (CO) releasing variant of Mesalazine (MesaCORM) having a structure according to Formula Ia or Ib; or a pharmaceutically acceptable salt thereof.

The present application relates to a kind of preparation and application of recombinant protein for inflammatory bowel disease treatment, and the gene of the recombinant protein is derived from intestinal bacteria Akkermansia muciniphila, and the name is Amuc_1434.The present application research shows that the recombinant protein has good therapeutic effect on inflammatory bowel disease.We successfully cloned Amuc_1434 gene into e. coli expression vector, then after induction expression purification, the recombinant protein Amuc_1434 is obtained.Experiments show that the recombinant protein Amuc_1434 provided by the present application can significantly alleviate the symptoms of UC mice, slow down the shortening of colon, reduce the level of inflammatory cytokines, reduce the body oxidative stress, reduce the degree of intestinal tissue lesions.In addition, the recombinant protein Amuc_1434 also shows the protective effect on kidney, and the effect is better than the common colitis treatment drug mesalazine on the market.The present application provides scientific basis for the application of recombinant protein Amuc_1434 in inflammatory bowel disease treatment, and lays a foundation for further development of new recombinant protein drug for inflammatory bowel disease treatment.

Disclosed herein are compositions and methods for the treatment of inflammatory bowel disease. According to some embodiments, the compositions and methods involve the use of a delayed-release capsule formulation containing a mesalamine layer, a hyaluronan layer, and at least one coating layer.

The invention relates to microparticles comprising a solid core that comprises mesalazine and a polymeric binder, wherein the core has a particle size distribution with d50 of 20-100 µm and span lower than 2.5, and wherein the core comprises at least 75 wt% of mesalazine based on the total weight of the core. The invention also refers to a method for the manufacture of the microparticles, to a pharmaceutical composition comprising the microparticles and to the use of the microparticles in the prevention or treatment of an inflammatory bowel disease, such as ulcerative colitis or Crohn's disease.

The invention belongs to the technical field of animal medicine, and discloses a pharmaceutical composition for preventing or treating porcine epidemic diarrhea. The paeoniflorin extract, the pawpaw total triterpenes, the mesalazine, the honeysuckle flower water extract and the mannan oligosaccharide are scientifically compounded, so that multi-target synergistic treatment is realized. Mesalazine can inhibit intestinal inflammation, and pawpaw total triterpenes can relieve oxidative damage and protect intestinal epithelium; the honeysuckle water extract is used for blocking virus infection, and the paeoniflorin extract is used for repairing intestinal villi; and the mannan oligosaccharide can regulate intestinal flora. All the components have a synergistic effect, the porcine epidemic diarrhea symptom is effectively controlled, the intestinal function is repaired, the cad pig incidence rate is reduced, and compared with a traditional scheme, pig herd health and breeding benefits can be more efficiently guaranteed.

The invention discloses application of bacteroides xylanolyticum capable of promoting intestinal bacteria to produce propionic acid and a composition of the bacteroides xylanolyticum in relieving ulcerative colitis, and belongs to the technical field of microorganisms. The bacteroides xylanolyticus NSP016 disclosed by the invention can quickly utilize konjac glucomannan, and the composition of the bacteroides xylanolyticus and konjac glucomannan can improve the rise of histopathologic score of mice with ulcerative colitis, maintain the integrity of intestinal barriers, reduce the oxidative stress level and remarkably reduce the level of clinical diagnosis markers of colitis, so that the clinical diagnosis of colitis is facilitated. The effect is better than that of a clinical medicine mesalazine. The bacteroides xylanolyticum NSP016 and the composition thereof disclosed by the invention have very wide application prospects in the aspect of preparing foods, pharmaceutical compositions, health-care products or feed additives for relieving ulcerative colitis.

The invention provides a mesalazine-containing slow-release solid dispersion and a preparation method thereof, and provides a mesalazine-containing slow-release solid dispersion in order to solve the problems that the existing mesalazine solid dispersion is poor in stability, free of targeting and easy to degrade in the preparation process. The solubility is high (the solubility is improved by 25-30 times compared with that of an original drug), the sustained release within 12 hours is controllable (accurate release in a colon segment, and the cumulative release rate within 12 hours reaches 85-90%), and the accelerated storage stability is high (the crystallization rate lt in 6 months; 3%, and the drug content gt; 98% and the ethanol residue 1t; 0.3%) and the like. The sustained-release solid dispersion provided by the invention and pharmaceutically acceptable auxiliary materials are prepared into sustained-release tablets or sustained-release capsules, and the sustained-release solid dispersion can be used for preparing oral preparations for treating inflammatory bowel diseases, can improve the drug concentration of diseased regions of intestinal tracts and reduce untoward effects of the whole body, and has remarkable clinical application value.

The invention discloses a preparation method of mesalazine sustained-release granules and the sustained-release granules. The sustained-release granule comprises a mesalazine drug-containing granule core and a sustained-release coating layer wrapping the mesalazine drug-containing granule core, and the sustained-release coating layer is made of an azobenzene methacrylate copolymer. After oral administration, the coating layer can completely pass through the upper digestive tract and reach the colon, azo bonds in the structure of the coating layer can be specifically degraded by special azo reductase in the colon, so that the coating layer is gradually damaged to form a diffusion channel, and mesalazine can be slowly and continuously released at the colon part along with the expansion of the channel; and accurate colon targeted drug delivery is realized. According to the invention, premature release of the medicine in the stomach and the small intestine and possible burst release risk are effectively avoided, and the concentration and curative effect of the medicine in the diseased region are remarkably improved. In addition, the granule dosage is convenient for dose adjustment, the production process is simple, and the granule has a good clinical application prospect.

According to the application of the canparolone in preparation of the medicine for preventing or treating the inflammatory bowel disease, animal experiments show that the canparolone can effectively increase the body weight of a mouse with ulcerative colitis, reduce the disease activity index and increase the colon length, the colon form score and the intestinal mucosa injury index score can be reduced, and the application of the canparolone in preparation of the medicine for preventing or treating the inflammatory bowel disease is achieved. The pharmaceutical composition can be used for treating ulcerative colitis, can also reduce the level of proinflammatory factors and effectively improve the symptoms of ulcerative colitis, has an effect superior to that of positive control medicine mesalazine, and has obvious clinical development value.